PuSH - Publikationsserver des Helmholtz Zentrums München

Kuhn, L. ; Valentin, S. ; Stojanovic, K. ; Strobl, D.C. ; Babushku, T. ; Wang, Y. ; Rambold, U. ; Scheffler, L. ; Grath, S.* ; John-Robbert, D.* ; Blum, H.* ; Feuchtinger, A. ; Blutke, A. ; Weih, F.* ; Kitamura, D.* ; Rad, R.* ; Strobl, L.J. ; Zimber-Strobl, U.

RelB contributes to the survival, migration and lymphomagenesis of B cells with constitutively active CD40 signaling.

Front. Immunol. 13:913275 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Activation of CD40-signaling contributes to the initiation, progression and drug resistance of B cell lymphomas. We contributed to this knowledge by showing that constitutive CD40-signaling in B cells induces B cell hyperplasia and finally B cell lymphoma development in transgenic mice. CD40 activates, among others, the non-canonical NF-ĸB signaling, which is constitutively activated in several human B cell lymphomas and is therefore presumed to contribute to lymphopathogenesis. This prompted us to study the regulatory role of the non-canonical NF-ĸB transcription factor RelB in lymphomagenesis. To this end, we crossed mice expressing a constitutively active CD40 receptor in B cells with conditional RelB-KO mice. Ablation of RelB attenuated pre-malignant B cell expansion, and resulted in an impaired survival and activation of long-term CD40-stimulated B cells. Furthermore, we found that hyperactivation of non-canonical NF-кB signaling enhances the retention of B cells in the follicles of secondary lymphoid organs. RNA-Seq-analysis revealed that several genes involved in B-cell migration, survival, proliferation and cytokine signaling govern the transcriptional differences modulated by the ablation of RelB in long-term CD40-stimulated B cells. Inactivation of RelB did not abrogate lymphoma development. However, lymphomas occurred with a lower incidence and had a longer latency period. In summary, our data suggest that RelB, although it is not strictly required for malignant transformation, accelerates the lymphomagenesis of long-term CD40-stimulated B cells by regulating genes involved in migration, survival and cytokine signaling.
Impact Factor
Scopus SNIP
Altmetric
8.786
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cd40 ; Non-canonical Nf-kappa B-signaling ; Relb ; Il9r ; Transgenic Mice ; B Cell Lymphoma ; Migration ; Lilrb4
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Quellenangaben Band: 13, Heft: , Seiten: , Artikelnummer: 913275 Supplement: ,
Verlag Frontiers
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
Institute of Computational Biology (ICB)
Institute of Asthma and Allergy Prevention (IAP)
CF Pathology & Tissue Analytics (CF-PTA)
Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
30202 - Environmental Health
Forschungsfeld(er) Immune Response and Infection
Enabling and Novel Technologies
Allergy

Lung Research
PSP-Element(e) G-501500-003
G-503800-001
G-503300-001
A-630600-001
G-505000-007
Förderungen Deutsche Krebshilfe
Deutsche Forschungsgemeinschaft
Scopus ID 85137868327
PubMed ID 36110848
Erfassungsdatum 2022-11-09